A5036486081- Asthma and respiratory diseases
- Respiratory and Cough-Related Research
- Cystic Fibrosis Research Advances
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Inhalation and Respiratory Drug Delivery
- Allergic Rhinitis and Sensitization
- Tracheal and airway disorders
- Pediatric health and respiratory diseases
- Neonatal Respiratory Health Research
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Child Nutrition and Feeding Issues
- Pharmaceutical studies and practices
- Dysphagia Assessment and Management
- Respiratory Support and Mechanisms
- Sinusitis and nasal conditions
- Clinical Nutrition and Gastroenterology
- Eosinophilic Esophagitis
- Sexual function and dysfunction studies
- Antifungal resistance and susceptibility
- Health Systems, Economic Evaluations, Quality of Life
- Airway Management and Intubation Techniques
- Developmental and Educational Neuropsychology
- Parathyroid Disorders and Treatments
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Urticaria and Related Conditions
Hospital Costa del Sol
2016-2025
Hospital Clínico Universitario Virgen de la Victoria
2025
Guy's and St Thomas' NHS Foundation Trust
2024
Agencia Sanitaria Costa del Sol
2017-2022
Hospital Doctor José Molina Orosa
2022
Hospital Regional Universitario de Málaga
2007-2022
State Duma
2017
Instituto de Neurologia Y Neurocirugia
1958
Sociedad de Neurología, Psiquiatría y Neurocirugía
1958
Hospital Roberto del Rio
1954
Background Pivotal phase 3 trials and real-world studies have demonstrated benralizumab's overall efficacy safety in severe eosinophilic asthma (SEA). Additional large-cohort data are needed to confirm its effectiveness SEA according previous biologic use key baseline characteristics important for treatment selection. Methods XALOC-1 is a large, multinational, retrospective, observational, study programme of benralizumab adults with SEA. This 48-week integrated analysis assessed annualised...
The efficacy of omalizumab in severe asthma has been widely demonstrated. main objective this study was to evaluate the and tolerability a real-life setting Spain, particularly those patients with immunoglobulin E (IgE) levels out range.Totally 266 uncontrolled receiving high-dose inhaled corticosteroids (ICSs) plus long-acting β2-agonist (LABA) were recruited. Main outcomes exacerbation rate (AER), control test (ACT), global evaluation treatment effectiveness (GETE).AER reduced from 3.6...
Some studies have reported a high prevalence of bronchiectasis in patients with uncontrolled asthma, but the factors associated this condition are unknown. The objective study was to determine moderate-to-severe asthma and identify risk their correlation these patients. This is prospective data from consecutive asthma. Diagnosis based on high-resolution computed tomography. A prognostic score developed using logistic regression model, which used bronchiectasis. total 398 (60% severe asthma)...
Abstract Background Benralizumab is a monoclonal antibody that binds to the human interleukin-5 (IL-5) receptor (IL-5R), thereby preventing IL-5 from binding its and inhibiting differentiation maturation of eosinophils in bone marrow. Because recent marketing approval, sufficient real-life evidence lacking confirm efficacy safety data clinical trials. The purpose this study was evaluate benralizumab for treatment severe refractory eosinophilic asthma real-world cohort patients. Methods This...
The ORBE II study aimed to describe the characteristics and clinical outcomes of adult patients with severe eosinophilic asthma (SEA) treated benralizumab in a real-world setting Spain.ORBE (NCT04648839) was an observational, retrospective cohort SEA who had been prescribed benralizumab. Demographic data 204 were collected 12 months prior initiation (baseline) at follow-up. Exacerbation rate, symptoms, maintenance oral corticosteroid (OCS) use lung function evaluated, among other variables.A...
Severe asthma is a heterogeneous syndrome with several clinical variants and often represents complex disease requiring specialized multidisciplinary approach, as well the use of multiple drugs. The prevalence severe varies from one country to another, it estimated that 50% these patients present poor control their disease. For best management patient, necessary correct diagnosis, an adequate follow-up undoubtedly offer available treatment, including biologic treatments monoclonal...
En este trabajo presentamos varios software de código libre diseñados para el análisis datos secuenciación masiva microbiomas con objetivo investigar las resistencias a antimicrobianos (RAM) una premisa principal: que sean fáciles usar. TORMES 2.0, transTORMES y torMAGs pueden trabajar directamente desde los archivos crudos permiten completo genomas bacterianos, la recuperación MAGs metagenomas RNAseq. Respectivamente. ChroQueTas permite RAM en fúngicos, buscando mutaciones genes diana antifúngicos.
Plain Language SummaryWhat is this summary about?This a of an article originally published in the European Respiratory Journal, which presented combined results from five retrospective real-world studies (i.e., looking at data collected during historical medical appointments) that each took place different country and which, together, formed XALOC-1 study programme. looked how effective benralizumab injections were clinical practice treating type asthma called 'severe eosinophilic...
El asma grave constituye un síndrome heterogéneo con múltiples variantes clínicas y representa el último peldaño en la patología asmática relación su gravedad. La prevalencia del entre los pacientes asmáticos varía de país a otro, se estima que 50% estos graves tienen mal control enfermedad. Para mejor manejo paciente es necesario correcto diagnóstico, seguimiento sin duda ofrecerle tratamiento disponible, incluyendo nuevos avances farmacológicos, como son anticuerpos monoclonales. Con este...
Reslizumab is an anti-interleukin 5 monoclonal antibody that has demonstrated to reduce the risk of severe exacerbations and improve symptoms, lung function, quality life in randomized controlled trials included patients with eosinophilic uncontrolled asthma (SEUA) a history exacerbations.The aim present study was evaluate effectiveness add-on reslizumab cohort SEUA under real-life conditions.This multi-centre, retrospective, subjects treated 44 units throughout Spain. Eligible were those...
Knowing the cost of hospitalizations for exacerbation in bronchiectasis patients is essential to perform cost-effectiveness studies treatments that aim reduce exacerbations these patients.To find out mean due patients, and identify factors associated with higher costs.Prospective, observational, multicenter study adult hospitalized exacerbation. All expenses from patients' arrival at hospital their discharge were calculated: diagnostic tests, treatments, transferals, home hospitalization,...
Abstract Background Availability of clinically effective and cost-effective treatments for severe asthma would be beneficial to patients national healthcare systems. The aim this study was evaluate clinical outcomes expenditure after incorporating benralizumab into the standard treatment refractory eosinophilic asthma. Methods This a cross-sectional multicentre consecutive with who received during at least 12 months. Patient follow-up performed in specialised units. main effectiveness...
The relative importance of the usual diet in serum phospholipids subjects with cystic fibrosis (CF) has been poorly studied. To compare fatty acid profile from adult CF that healthy subjects, and determine role normal this profile, we studied thirty-seven stable pulmonary disease controls matched for age, sex nutritional status. A dietary questionnaire was obtained, anthropometric data were recorded, measured by GLC. Compared controls, percentages myristic, palmitoleic stearic acids total...
There is limited information on the causes of death in asthma patients. To determine hospitalized asthmatic patients and to compare with those observed COPD non-respiratory individuals, a particular interest associations previous cardiovascular disease. Retrospective case–control study which analyzed deaths all admitted for any reason during January, April, July October 2008 13 Spanish centers. Medical records deceased were reviewed, demographic clinical data collected. A total 2,826 (mean...
Abstract: This paper, developed by consensus of staff physicians accredited asthma units for the management severe asthma, presents information on process and requirements already-existing to achieve official accreditation Spanish Society Pneumology Thoracic Surgery (SEPAR). Three levels specialized care have been established based available resources, which include highly complex units, basic units. Regardless level obtained, distinction "excellence" could be granted when more in areas...